Biotech Values

[DewDiligence]

What became of Esperion?

From the Q&A session of PFE’s R&D webcast yesterday:

“…a small biotech company like Esperion doesn’t necessarily have the resources to do all the things that are needed to get things ready for long-term trials… The synthesis and the analytics around the material that they had available at that time really weren’t robust enough for us to be able to start phase-3. So we’ve had to go back and do a lot of work around that. I think we’ve pretty much figured all that out and solved those problems… We hope to move into phase-2b studies in the next year.”
—John LaMattina, President, Pfizer R&D